JAK inhibitors raise shingles risk, so timing the vaccine matters. A randomized trial found a trade-off between a stronger vaccine response and faster arthritis relief.
Kobe University researchers mass-produced iPSC-derived γδ T cells that cut tumor weight by up to 88% in mice — a step toward cheaper, ready-made cell therapy.
A new analysis explains the paradox: GLP-1 drugs are cost-effective per patient, yet the sheer number of eligible people makes broad coverage financially daunting for insurers.
An algorithm hunting through human genes surfaced BRP, a natural peptide that curbed appetite in mice and pigs without the nausea seen with GLP-1 drugs.
Lab-grown human neurons show the protective APOE2 variant is better at repairing DNA damage and resisting the cellular aging linked to neurodegeneration.
Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.
New Triumph trial data show 21–23% weight loss in patients with diabetes or heart disease, setting up a 2027 filing for Lilly's triple-hormone drug.
Patients report hunting across pharmacies for the Lantus SoloStar pen, which Sanofi says is temporarily constrained by rising demand.
Mapping genome architecture and gene activity in the same cells reveals a new layer of dysfunction in Alzheimer's — and possible therapeutic targets.
The CRISPR biotech, which silences genes without cutting DNA, priced a modest offering in a cautious market — a notable reopening for gene-editing listings.
Surgeons warn that colorectal cancer is now the leading cause of cancer death in people under 50, and subtle symptoms are too often dismissed.
A 2026 systematic review finds semaglutide and tirzepatide carry a higher hair-loss signal than older GLP-1 drugs — though the shedding appears reversible.